# US 2010/0146660 A1 · Process for micropropagation of pogostemon cablin from a meristematic explant

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0146660 A1
- Document ID: US20100146660A1
- Status: Published application
- Kind: A1
- Application number: 12/295,034
- Filed: 2007-03-30
- Published: 2010-06-10
- Earliest claimed: 2006-03-31
- Assignees: Reliance Life Sciences Pvt. Ltd.
- Inventors: Sreenivasachar Murali Krishnapuram; Neera Pandey; Shailendra Baviskar; Ghanshyam Maurya
- Web page: https://patentgrep.com/patent/US20100146660A1

## CPC

- A01H 4/005: {Methods for micropropagation; Vegetative plant propagation using cell or tissue culture techniques}
- A01H: NEW PLANTS OR {NON-TRANSGENIC} PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES

## Abstract

The present invention provides a commercially viable process for in vitro propagation of patchouli (Pogostemon cablin). The process involves direct organogenesis from meristematic explants employing a simple and cost effective media and shows about 90% survival upon transfer to in vivo conditions.

## Claims

### Claim 1

A method for producing a true-to-type clone of a Pogostemon cablin mother plant comprising
selecting a Pogostemon cablin mother plant;
isolating a meristematic explant from said plant;
culturing said meristematic explant in initiation medium to generate shoots;
culturing said shoots in proliferation and elongation medium to generate elongated shoots, wherein said proliferation and elongation medium comprises benzyl adenine (BA) and adenine sulfate (AS);
culturing said elongated shoots in rooting medium to generate plantlets, wherein said rooting medium comprises indole acetic acid (IAA); and
culturing said plantlets to produce a true-to-type clone of said Pogostemon Cablin mother plant.

### Claim 2 (depends on 1)

The method of claim 1, wherein said initiation medium, proliferation and elongation medium, and rooting medium have the same concentration of basal salts.

### Claim 3 (depends on 1)

The method of claim 1, wherein said meristematic explant is treated to reduce microbial contamination.

### Claim 4 (depends on 1)

The method, of claim 1, wherein said meristematic explant is from a shoot tip or a nodal bud.

### Claim 5 (depends on 1)

The method of claim 1, wherein said meristematic explant is from a shoot tip.

### Claim 6 (depends on 5)

The method of claim 5, wherein said shoot tip comprises bud tissue.

### Claim 7 (depends on 6)

The method of claim 6, wherein said bud tissue is apical bud tissue.

### Claim 8 (depends on 7)

The method of claim 7, wherein said bud tissue is axillary bud tissue.

### Claim 9 (depends on 1)

The method of claim 1, wherein said BA is at a concentration from about 0.5 mg/L to about 2.0 mg/L.

### Claim 10 (depends on 9)

The method of claim 9, wherein said BA is at a concentration selected from the group consisting of: about 0.5 mg/L, about 1.0 mg/L, about 1.5 mg/L, and about 2.00 mg/L.

### Claim 11 (depends on 10)

The method of claim 10, wherein said BA is at a concentration of about 0.5 mg/L.

### Claim 12 (depends on 1)

The method of claim 1, wherein said AS is at a concentration from about 1 mg/L to about 10 mg/L.

### Claim 13 (depends on 12)

The method of claim 12, wherein said AS is at a concentration selected from the group consisting of: about 1.0 mg/L, about 5 mg/L, and about 10 mg/L.

### Claim 14 (depends on 13)

The method of claim 13, wherein said AS is at a concentration of about 5 mg/L.

### Claim 15 (depends on 1)

The method of claim 1, wherein said IAA is at a concentration from about 1 mg/L to about 10 mg/L.

### Claim 16 (depends on 15)

The method of claim 15, wherein said IAA is at a concentration selected from the group consisting of: about 1.0 mg/L, about 5 mg/L, and about 10 mg/L.

### Claim 17 (depends on 16)

The method of claim 16, wherein said IAA is at a concentration of about 5 mg/L.

### Claim 18

The method according to claims hereinabove substantially as herein described with reference to the examples and figures.
